Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | CBFB | Q13951 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455883 | 0.85 | GUSB (0.42) | NPC1RAB9AATMALDH1A1MAPT | |
| SCHEMBL13070128 | 0.78 | DRD2 (0.38) | NPC1RAB9APDGFRBFGFR1KDR | |
| SCHEMBL14031961 | 0.78 | KDM4E (0.38) | KDM4EALDH1A1MAPTHPGDTP53 | |
| SCHEMBL3455894 | 0.78 | GAA (0.49) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL3455923 | 0.78 | KMT2A (0.40) | NPC1RAB9ADGAT1KDM4EALDH1A1 | |
| SCHEMBL3456715 | 0.77 | ATM (0.38) | ADORA3METAP1METAP2CBFBSYK | |
| SCHEMBL3456017 | 0.76 | ALPL (0.42) | NPC1RAB9AKDM4ETP53GAA | |
| SCHEMBL3455100 | 0.74 | BRD4 (0.38) | ADORA3METAP1METAP2CBFBNPC1 | |
| SCHEMBL3455109 | 0.73 | NPC1 (0.40) | ADORA3METAP1METAP2CBFBNPC1 | |
| SCHEMBL14031952 | 0.73 | HPSE (0.41) | NPC1RAB9AATMERAP1AMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251340-A1 | Substituted tetrahydro-1h-pyrazolo[3,4-c] pyridines, compositions containing same and use thereof | Aventis Pharma S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| EP-2251340-A1 | Substituted tetrahydro-1h-pyrazolo[3,4-c] pyridines, compositions containing same and use thereof | Aventis Pharma S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7109340-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2006-09-19 | — | — | US | disclosed |
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-07 | — | — | US | disclosed |
| EP-1646632-A2 | SUBSTITUTED TETRAHYDRO-1 I H /I -PYRAZOLO 3,4-C|PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | Aventis Pharma S.A. (FR) | 2006-04-19 | — | — | EP | disclosed |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2005-05-05 | — | — | US | disclosed |
| WO-2005007653-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | BRD4, TP53, HCCS | GRIN2D 2850/4885GRIN3B 827/4885GRIN1 1712/4885 |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | BRD4, TP53, HCCS | GRIN2D 2577/4885GRIN3B 634/4885GRIN1 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.